

ARCH: Avedro Reimbursement Customer Hub

Benefits of Enrollment:

- Sample templates for appeal letters
- Online portal for tracking and managing appeal cases
- Pre-service support for authorizations and appeals
- Post-service support for denied or low-paid claim appeals
- Eligibility to apply for Patient and Rx Assistance Programs

Program Services:

- Assistance from reimbursement specialists
- Payer-specific medical coverage policy research
- Reference materials such as billing and coding guides
- Support with reimbursement from commercial payers
- Troubleshooting denied claims and advice for next steps

Contact ARCH:

Hotline: 844-528-3311

Fax: 844-528-3322

E-Mail: Info@avedroARCH.com

Hours: Monday - Friday

9:00 am – 8:00 pm EST

8:00 am – 7:00 pm CST

6:00 am – 5:00 pm PST

The ARCH Program offers information and resources to providers to navigate coverage and reimbursement from commercial payers for Photrexa® Viscous, Photrexa® and the corneal collagen cross-linking procedure.

Interested providers should reach out to a reimbursement specialist today to learn how the ARCH Program can support you and your patients.



The World Leader in Corneal Remodeling™

To find out more about the ARCH Program, please visit our website: Avedro.com/ARCH

Avedro does not provide information about coverage and reimbursement for patients covered by Medicare, Medicaid, or other government healthcare programs. Photrexa® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146%, Photrexa® (riboflavin 5'-phosphate ophthalmic solution) 0.146% and the KXL® System are marketed by Avedro, Inc. Full prescribing information can be found at <http://avedro.com/en-us/>

Patient Assistance Program*

The Avedro Patient Assistance Program provides Photrexa® Viscous and Photrexa® at no charge to financially eligible, uninsured patients and patients with government-funded insurance.

ARCH Program

The Avedro Reimbursement Customer Hub (ARCH) offers providers information and resources to navigate coverage and reimbursement from commercial payers for Photrexa® Viscous, Photrexa® and the corneal collagen cross-linking procedure.

Prescription Assistance Program*

The Avedro Prescription Assistance Program offers providers a discount on a future Photrexa® Viscous and Photrexa® purchase when reimbursement from commercial payers is denied or below acquisition cost.

*Interested patients should contact ophthalmology practices who are enrolled in the ARCH Program for more information and to see if they qualify for financial assistance.

Avedro Reimbursement Customer Hub Programs

To find out more about the ARCH Program, please visit our website: Avedro.com/ARCH

IMPORTANT SAFETY INFORMATION

INDICATIONS Photrexa® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5'-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking (CXL) for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

LIMITATIONS OF USE The safety and effectiveness of CXL has not been established in pregnant women, women who are breastfeeding, patients who are less than 14 years of age and patients 65 years of age or older. Photrexa Viscous and Photrexa should be used with the KXL System only.

WARNINGS AND PRECAUTIONS Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.

ADVERSE REACTIONS In progressive keratoconus patients, the most common ocular adverse reactions in any CXL treated eye were corneal opacity (haze), punctate keratitis, corneal striae, corneal epithelium defect, eye pain, reduced visual acuity, and blurred vision. In corneal ectasia patients, the most common ocular adverse reactions were corneal opacity (haze), corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, photophobia, reduced visual acuity, and blurred vision.

These are not all of the side effects of Photrexa® Viscous, Photrexa® and the CXL treatment. For more information, see Prescribing Information.

You should report an adverse event to Avedro by calling 1-844-528-3376, Option 1 or you may contact the U.S. Food and Drug Administration (FDA) directly at 1-800-FDA-1088.